A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis
- PMID: 10446007
- DOI: 10.1590/s0074-02761999000400011
A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis
Abstract
E10-5A3 is a dhfr-ts- Leishmania major double knockout auxotrophic shown previously to induce substantial protection against virulent L. major infection in both genetically susceptible and resistant mice. We investigated the capacity of dhfr-ts- to protect against heterologous infection by L. amazonensis. The degree of protection was evaluated by immunization of BALB/c or C57BL/6 mice with E10-5A3, followed by L. amazonensis challenge. Whether immunized by subcutaneous (SC) or intravenous (IV) inoculation, susceptible and resistant mice displayed a partial degree of protection against challenge with virulent L. amazonensis. SC-immunized BALB/c mice developed lesions 40 to 65% smaller than non immunized mice, while IV immunization led to protection ranging from 40 to 75% in four out of six experiments compared to non immunized animals. The resistant C57BL/6 mice displayed comparable degrees of protection, 57% by SC and 49% by IV immunization. Results are encouraging as it has been previously difficult to obtain protection by SC vaccination against Leishmania, the preferred route for human immunization.
Similar articles
-
Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.J Immunol. 2001 Feb 1;166(3):1921-9. doi: 10.4049/jimmunol.166.3.1921. J Immunol. 2001. PMID: 11160240
-
Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.Infect Immun. 2005 Sep;73(9):5842-52. doi: 10.1128/IAI.73.9.5842-5852.2005. Infect Immun. 2005. PMID: 16113303 Free PMC article.
-
Development of a safe live Leishmania vaccine line by gene replacement.Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10267-71. doi: 10.1073/pnas.92.22.10267. Proc Natl Acad Sci U S A. 1995. PMID: 7479765 Free PMC article.
-
An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines.Acta Trop. 2019 Dec;200:105173. doi: 10.1016/j.actatropica.2019.105173. Epub 2019 Sep 13. Acta Trop. 2019. PMID: 31525323 Review.
-
Recent trends in vaccine development and immunization.Clin Dermatol. 1999 May-Jun;17(3):339-44. doi: 10.1016/s0738-081x(99)00052-8. Clin Dermatol. 1999. PMID: 10384874 Review. No abstract available.
Cited by
-
A deficiency in the B cell response of C57BL/6 mice correlates with loss of macrophage-mediated killing of Leishmania amazonensis.Int J Parasitol. 2010 Feb;40(2):157-61. doi: 10.1016/j.ijpara.2009.11.010. Epub 2009 Dec 11. Int J Parasitol. 2010. PMID: 20004204 Free PMC article.
-
Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.Immunol Res. 2008;41(2):123-36. doi: 10.1007/s12026-008-8016-2. Immunol Res. 2008. PMID: 18389179 Review.
-
Inoculation of the Leishmania infantum HSP70-II Null Mutant Induces Long-Term Protection against L. amazonensis Infection in BALB/c Mice.Microorganisms. 2021 Feb 12;9(2):363. doi: 10.3390/microorganisms9020363. Microorganisms. 2021. PMID: 33673117 Free PMC article.
-
Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments.Vaccines (Basel). 2019 Oct 18;7(4):156. doi: 10.3390/vaccines7040156. Vaccines (Basel). 2019. PMID: 31635276 Free PMC article. Review.
-
Vaccination in Leishmaniasis: A Review Article.Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35. Iran Biomed J. 2022. PMID: 34952558 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources